COMP <GO>
CTKB vs ALMR // EV/EBITDA & P/E VALUATION
Cytek Biosciences Inc. (NASDAQ) VS. Alamar Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: CTKB 1
— ALMR 1
■ METRIC PARITY
LAST: $6.30 (+2.61%) • MKT CAP: $818.9M
valuation
—
LAST: $34.04 (-0.76%) • MKT CAP: $2.36B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTKB VS. ALMR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CTKB | ALMR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.80% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -12.70% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.07% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -20.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -33.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 0.50% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.76 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.6 | 50.8 | +14.82 | CTKB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $818.9M | $2.36B | -$1.54B | ALMR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CTKB REV | ALMR REV | CTKB GROSS % | ALMR GROSS % | CTKB FCF | ALMR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $201.5M | $0 | 51.8% | — | -$8.8M | — |
| FY 2024 | $200.5M | — | 55.4% | — | $21.9M | — |
| FY 2023 | $193.0M | — | — | — | $5.3M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTKB // BETA —
ALMR // BETA —